Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648975 | 0.87 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9848240 | 0.84 | CHRM3 (0.33) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9145027 | 0.84 | CHRM3 (0.33) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9145118 | 0.84 | CHRM3 (0.33) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL21057815 | 0.83 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL8529192 | 0.82 | CYP2C9 (0.38) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9145163 | 0.82 | CYP2C9 (0.38) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9146133 | 0.82 | CYP2C9 (0.38) | CYP2C9CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL27648705 | 0.81 | ALDH1A1 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9145099 | 0.81 | CYP2C9 (0.38) | CYP2C9CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324701-A1 | COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERS | DIAMEDICA, INC. (CA) | 2009-12-31 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007082381-A1 | COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERS | DIAMEDICA INC. (CA) | 2007-07-26 | — | — | WO | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-7087623-B2 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | CUNY GREGORY D (US) | 2004-11-25 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| WO-1996012486-A1 | USE OF [R-(Z)]-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCLO [2.2.2] OCT-3-YL) ACETONITRILE TO REDUCE AMYLOID BETA A4 FORMATION IN ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-05-02 | — | — | WO | disclosed |
| WO-1994022816-A1 | METAL CHELATING COMPOUNDS | AMERSHAM INTERNATIONAL PLC (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618191-A1 | Metal chelating compounds | AMERSHAM INTERNATIONAL plc (GB) | 1994-10-05 | — | — | EP | disclosed |
| EP-0369286-A2 | Dibenzozepine derivatives for treating acute and chronic obstructive diseases of the respiratory tract | Dr. Karl Thomae GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0346745-A1 | Condensed diazepinones, processes for their preparation and pharmaceutical preparations containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0346744-A1 | Condensed diazepinones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0346767-A2 | Use of 5,11-dihydro-6H-pyridino[2,3-b][1,4]benzodiazepin-6-one substituted in position 11 in the manufacture of a medicament for the treatment of Brady cardia and Brady arrhytmia in human and veterinary medicine | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0326066-A2 | Condensed diazepinones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-08-02 | — | — | EP | disclosed |
| EP-0324348-A2 | Derivatives of piperidincarboxamide for the treatment of Bradycardia and Bradyarrhythmia | Dr. Karl Thomae GmbH (DE) | 1989-07-19 | — | — | EP | disclosed |
| EP-0312895-A2 | Condensed diazepinones, process for their preparation and medicament containing them | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | CYP2C9 558/4885CHRM3 89/4885CHRM2 50/4885 |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | CYP2C9 4444/4885CHRM3 575/4885CHRM2 695/4885 |
| US-20090324701-A1 | COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERS | GPR119, SLC5A2, IAPP | CYP2C9 1178/4885CHRM3 2799/4885CHRM2 1250/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | CYP2C9 558/4885CHRM3 89/4885CHRM2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.